These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22038761)

  • 1. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.
    Garcia JA; Rini BI
    Cancer; 2012 May; 118(10):2583-93. PubMed ID: 22038761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H; Garcia JA
    Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abiraterone acetate in castration-resistant prostate cancer.
    Iacovelli R; Palazzo A; Procopio G; Gazzaniga P; Cortesi E
    Anticancer Drugs; 2012 Mar; 23(3):247-54. PubMed ID: 22123334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).
    Lee DJ; Cha EK; Dubin JM; Beltran H; Chromecki TF; Fajkovic H; Scherr DS; Tagawa ST; Shariat SF
    BJU Int; 2012 Apr; 109(7):968-85. PubMed ID: 22035221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and emerging treatments in the management of castration-resistant prostate cancer.
    Shapiro D; Tareen B
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic castrate-resistant prostate cancer: dawn of a new age of management.
    Masson S; Bahl A
    BJU Int; 2012 Oct; 110(8):1110-4. PubMed ID: 22564337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in second-line treatment of castration-resistant prostate cancer.
    Ong M; Winquist E
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):199-205. PubMed ID: 21734586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting continued androgen receptor signaling in prostate cancer.
    Massard C; Fizazi K
    Clin Cancer Res; 2011 Jun; 17(12):3876-83. PubMed ID: 21680543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel chemotherapies in development for management of castration-resistant prostate cancer.
    Tewari AK; George DJ
    Curr Opin Urol; 2013 May; 23(3):220-9. PubMed ID: 23511791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer.
    Clarke NW
    BJU Int; 2012 Oct; 110 Suppl 1():14-22. PubMed ID: 23046036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
    Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in castrate-resistant prostate cancer.
    Shore N; Mason M; de Reijke TM
    BJU Int; 2012 Jun; 109 Suppl 6():22-32. PubMed ID: 22672122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.